li Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Find Insider Deals for items perfect around the house and on the goFILE - A sign for Eli Lilly & Co. appears outside their corporate headquarters in Indianapolis on April 26, 2017. – E
Mounjaro sales more than tripled in the quarter to nearly $3.1 billion. Zepbound, which is made from the same molecule, brought in $1.2 billion two quarters after regulators approved the drug.TD Cowen analyst Steve Scala said in a research note that nearly all of the company’s key products beat sales expectations for the quarter. That list includes the insulin Humalog, with $632 million in revenue.
Lilly also had raised its forecast beyond expectations when it reported first-quarter results in April.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA saysDemand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up…
Read more »
Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA saysDemand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up…
Read more »
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarThe success of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
Read more »
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarThe success of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
Read more »
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarThe success of Eli Lilly's weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
Read more »
Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales SoarRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »